Pharmacoeconomic Guidelines: The Netherlands

Country/Region: The Netherlands
PE Guidelines

Guideline for the Conduct of Economic Evaluations in Health Care (Dutch Version February 2016)
PDF in Dutch

PDF in English

PE Guidelines Source:
National Health Care Institute (ZIN)
Additional Information:

Costing Manual
PDF in Dutch

Manual on Quality of Life Measurements
PDF in Dutch

Uncertainty and Value of Information
PDF in English

Information current as of Monday, July 25, 2022

Key Features

Type of Guidelines PE Guidelines
Title and year of the document Guideline for the Conduct of Economic Evaluations in Health Care (Dutch Version February 2016)
Affiliation of authors National Health Care Institute
Purpose of the document Providing guidance for conduct of EE studies for reimbursement issues in order to improve their quality, credibility and comparability
Standard reporting format included Yes
Disclosure Yes
Target audience of funding/ author's interests Who conduct economic evaluations or evaluate the economic evaluations studies (decision makers)
Perspective Societal perspective. Report unrelated medical costs in life years gained seperately.
Indication Approved indication; although sometimes off-label use is considered for comparator
Target population Be clearly specify
Subgroup analysis Yes
Choice of comparator Standard of care or usual care in the Netherlands
Time horizon Life time
Assumptions required Yes
Preferred analytical technique CUA
Costs to be included Societal perspective. Report unrelated medical costs in life years seperately.
Source of costs Reference prices list should be used
Modeling Yes, requires details
Systematic review of evidences Yes, encourage meta-analysis
Preference for effectiveness over efficacy Yes, modelling on trial data and other sources is required
Preferred outcome measure QALY and optional other measures of effectiveness like life years gained (LYG)
Preferred method to derive utility EQ-5D-5L using Dutch value set
Equity issues stated Yes
Discounting costs 4%
Discounting outcomes 1.5%
Sensitivity analysis-parameters and range All key uncertain parameters, within a defined area and best/worst case scenario
Sensitivity analysis-methods One-way, multi-way or scenario and probabilistic analysis
Presenting results Must be clear. Total costs and effects, incremental costs and effects. Results sensitivity analysis in tables and appropriate figures
Incremental analysis Yes
Total costs vs effectiveness (cost/effectiveness ratio) Yes
Portability of results (Generalizability) Study must refer to national context; utilities preferable calculated using Dutch value sets
Financial impact analysis Yes
Mandatory or recommended or voluntary Mandatory


Saskia Knies, PhD, Pharmacoeconomics Advisor, Zorginstituut Nederland (ZIN), Diemen, The Netherlands and Maarten J. IJzerman, PhD, Professor of Clinical Epidemiology & Health Technology Assessment (HTA) and Head, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now